19th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and Myeloma
19th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaFebruary 20 - 21, 2015
100 Chopin Plaza
Miami, FL 33131
Phone: (305) 577-1000
The 19th Annual International Congress on Hematologic Malignancies®
Focus on Leukemias, Lymphomas, and Myeloma provides a unique opportunity for medical oncologists, hematologists, and other healthcare professionals to interact with international leaders in the field of hematologic malignancies.
This year, we've moved the meeting to Miami, Florida and welcome two new co-chairs.
will help you stay up-to-date and give you the information that you can integrate into your practice immediately.
Cases will focus on patient scenarios that you encounter in your practice
Hear the experts distill the data and pinpoint what you need to know
Presentations will hone in on the most relevant actionable information
Myron S. Czuczman, MD
Professor of Oncology
Chief, Lymphoma/Myeloma Service
Department of Medicine
Head, Lymphoma Translational Research Laboratory
Department of Immunology
Roswell Park Cancer Institute
Andre Goy, MD, MS
Chairman and Director
Lymphoma Division Chief
John Theurer Cancer Center at HackensackUMC
Chief Science Officer and Director of Research and Innovation of RCCA
Professor of Medicine, Georgetown University
This educational congress is directed toward medical oncologists and hematologists interested in the treatment of patients with hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies are also invited to attend.
Faculty, Staff, and Planners’ Disclosures
The following individuals have no relevant financial relationships with commercial interests to disclose:
Stefan Faderl, MD; Steven Horwitz, MD; Thomas Kipps, MD, PhD; Ola Landgren, MD, PhD; and Steven Treon, MD, PhD.
The staff of PER®, LLC: Ann C. Lichti, CHCP; David Lee PhD; and Megan O’Connell.
The following individuals have relevant financial relationships with commercial interests to disclose:
James Bussel, MD--
Grant/ Research Support: Amgen, Cangene, GlaxoSmithKline, Genzyme, BiologicTx, Immunomedics, Ligand, Eisai, Inc, Shionogi and Sysmex; Consultant: Amgen, GlaxoSmithKline, Ligand, Shionogi, Symphogen and Eisai (Ad Boards); Stock/ Shareholder: Amgen and GlaxoSmithKline.
Myron Czuczman, MD
-- Consultant: Algeta, Boehringer Ingelheim, Celgene, Gilead, Millennium, MorphoSys, Mundipharma, Teva, TG Therapeutics.
Dan Douer, MD
-- Grant/ Research Support: Sigma Tai, Amgen, Bristol-Myers Squibb; Consultant: Sigma Tau and Spectrum.
Randy Gascoyne, MD
-- Genentech, Roche, Celgene, Janssen and NanoString; Speaker’s Bureau-- Seattle Genetics.
Andre Goy, MD, MS
-- Johnson & Johnson, Celgene (clinical trial support though institution); Consultant: Celgene; Speaker’s Bureau: Takeda; Johnson & Johnson, Pharmacyclics; Other: Advisory Board: Celgene, Takeda, Pharmacyclics, Johnson& Johnson.
Sundar Jagannath, MD
-- Consultant: Celgene, Sanofi.
Jeffrey Jones, MD, MPH
-- Grant Research: Genentech, Abbvie, Gilead, Pharmacyclics.
Jonathan Kaufman, MD
-- Grant/ Research Support: Celgene, Merck, Novartis, Onyx; Consultant: Millennium, Celgene, Onyx, Novartis, Janssen, Spectrum.
Rami Komrokji, MD
-- Grant/ Research Support: Celegene, Incyte, GlaxoSmithKline; Consultant: Celgene, Incyte; Speaker’s Bureau: Novartis.
Shuo Ma, MD, PhD
-- Grant/ Research Support: NCCN, GSK, Pharmacyclics, Gilead, Abbvie, Celgene, Xeme Biopharma; Consultant: Pharmacyclics, Gilead; Speaker’s Bureau: Genentech, Janssen, Gilead.
David Maloney, MD, PhD
-- Grant/ Research Support: Juno Therapeutics; Consultant: Roche/Genentech; Janssen Scientific Affairs, LLC; Seattle Genetics; Spectrum.
Michael Mauro, MD
-- Grant/ Research Support: Novartis Oncology; Consultant: Novartis Oncology, Bristol-Myers Squibb, Pfizer, Ariad.
Eduardo Sotomayor, MD
-- Grant/ Research Support: Acetylon Pharmaceuticals, FORMA Pharmaceuticals; Consultant: Genentech, Seattle Genetics, Gilead, Celgene.
Moshe Talpaz, MD
-- Grant/ Research Support: Pfizer, Noavartis, Ariad, Sanofi, Incyte.
William Wierda, MD, PhD
-- GlaxoSmithKline, AbbVie, Genentech, Karyopharm, Pharmacyclics, Ascerta, Gilead, Jansen; Consultant: Sanofi, Genentech/Roche, Pharmacyclics, Celgene, Gilead, GlaxoSmithKline, Gensyme, Merck, AbbVie, Emergent.
Thomas Witzig, MD
-- Grant/ Research Support: Celgene, Novartis, Spectrum; Other: Ad Board: Amgen.
Anas Younes, MD
-- Grant/ Research Support: Novartis, Johnson& Johnson, Curis; Other: Honorarium from: Bayer; Bristol-Myers Squibb, Celgene, Janssen, Sanofi, Seattle Genetics, Takeda, Millennium.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.